The investor funk that kept biotech stocks down for about half of this year helps explain why private funding of early-stage biopharmas slipped during the first three quarters of 2016, according to one key measure. Between January and September, a total $5.3 billion in venture capital was invested in 305 early-stage companies (compared with $6 billion in 371 in the same period last year), according to the quarterly MoneyTree™ Report published by PricewaterhouseCoopers (PwC), based on data from Thomson Reuters.

But this year’s GEN tally of early-stage drug and diagnostic developers that closed on millions of dollars in private funding during 2016 (as of deadline on December 2) tells another story.

Of the top 10 financings that made this List, four were announced since October 1, reflecting renewed investor confidence in biopharma—a sentiment that gained steam in the weeks since Donald Trump’s election caused market-watchers to conclude that Washington will be unlikely to contain ever-rising drug prices once he takes office.

That bounceback aside, the combined amount of the top 10 “Young Company” biotech financings within this year was down 8.4% from 2015—$2.030 billion, compared with $2.217 billion in 2015. This year’s top financing was recorded by the same company that topped last year’s list, and was even larger than the financing that topped the 2015 List.

As was the case with GEN Lists published last year, in 2014, and in 2013, this year’s tally does not include companies that secured private funding and later went public, or filed registration statements to do so. None of the companies on this year’s list meets that category.

Also not included are public companies that raised large sums of private funding. Only one such company would have otherwise made this year’s list—MorphoSys, which on November 15 said it raised approximately €115 million (about $123 million) in a private placement in which it issued 2,622,088 new shares to institutional investors in Europe and North America at €44 ($49) per share.

#10. DalCor Pharmaceuticals

Amount: $110 million1

Type: Series B financing

Date announced: April 19, May 131,2

Purpose: Fund a Phase III trial of dalcetrapib, a CETP inhibitor, in patients who have recently experienced acute coronary syndrome

Financing leaders: New investors Caisse de dépôt et placement du Québec, the Fonds de solidarité FTQ, and CTI Life Sciences; Founding investors Sanderling Ventures and André Desmarais

Additional financial partners: Undisclosed investors

#9. Unity Biotechnology

Amount: $116 million

Type: Series B financing

Date announced: October 27

Purpose: Expand ongoing research programs in cellular senescence and advance the first preclinical programs into human trials

Financing leader: None denoted

Financial partners: ARCH Venture Partners, Baillie Gifford, Fidelity Management and Research Company, Partner Fund Management, and Venrock (all new investments); Other investors include Bezos Expeditions, the investment vehicle of CEO Jeff Bezos, and existing investors WuXi PharmaTech and Mayo Clinic Ventures

#7 (tie). Denali Therapeutics

Amount: $130 million

Type: Series B financing

Date announced: August 25

Purpose: Fund the company’s therapeutic pipeline and blood-brain-barrier delivery technology platform

Financing leader: Baillie Gifford

Additional financial partners: All of Denali’s founding investors—which include ARCH Venture Partners, F-Prime Biosciences, Flagship Ventures, and the Alaska Permanent Fund—as well as “several new and large institutional investors.”

#7 (tie). Zymergen

Amount: $130 million

Type: Series B financing

Date announced: October 11

Purpose: Accelerate growth to further support customers, in addition to recruiting top talent across software engineering, automation, and biology

Financing leader: SoftBank Group

Additional financial partners: New investors Iconiq Capital, Prelude Ventures, and Tao Capital Partners; Prior lead investor Data Collective; Return investors True Ventures, AME Cloud Ventures, DFJ, Innovation Endeavors, Obvious Ventures, and Two Sigma Ventures

#6. CStone Pharmaceuticals

Amount: $150 million

Type: Series A financing

Date announced: July 3

Purpose: Focus on addressing the specific needs of Chinese patients, by developing a pipeline that covers five therapeutic areas, including its core therapeutic focus of immuno-oncology, as well as cardiovascular diseases, rheumatoid arthritis, hematology, and autoimmune diseases

Financing leader: None specified

Financing partners: Oriza Seed Venture Capital, Boyu Capital, and WuXi Healthcare Ventures

#5. Intarcia Therapeutics

Amount: $215 million3

Type: Equity financing

Date announced: September 15

Purpose: Positioning company toward a “strong strategic and financial position” over the next 2–3 years as it prepares for the potential approval and launch late next year of ITCA 650 (continuous subcutaneous delivery of exenatide), a once- or twice-yearly therapy for the chronic treatment of type 2 diabetes; and the parallel progression of several novel pipeline programs in chronic diseases that include diabetes, obesity, and auto-immune/inflammation

Financing leader: None specified

Financial partners: Undisclosed new “world-class” institutional investors, family offices, a “large and long-term” VC/private equity fund of Lucion Venture Capital Group, and undisclosed existing investors “that have come into the company over the last 5–6 years”

#4. Human Longevity

Amount: “In excess of” $220 million

Type: Series B financing

Date announced: April 4

Purpose: Fund the growth and expansion of the company and its products: these include the first Health Nucleus, HLI’s comprehensive, genomic-enhanced, research-based health center; ongoing development of the HLI Knowledgebase which currently has more than 20,000 complete genomes coupled with phenotype data; the Comprehensive Cancer Program, and other sequencing programs

Financing leaders: None denoted

Financial partners: Illumina, Celgene, GE Ventures, and a “strong” participation from Series A investors, based in the U.K., Malaysia, Mexico, Australia, Kuwait, Hong Kong, and China, in addition to the U.S.

#3. BlueRock Therapeutics

Amount: $225 million

Type: Series A financing

Date announced: December 12

Purpose: Give company at least four years of runway; allow company to advance a number of programs into the clinic, with an initial focus on cardiovascular diseases and neurodegenerative disorders. Company aims to develop best-in-class induced pluripotent stem cell (iPSC) therapies

Financing leaders: Bayer and Versant Ventures.

Additional financial partners: None denoted

#2. Innovent Biologics

Amount: $260 million

Type: Series D financing

Date announced: November 29

Purpose: Accelerate the company’s continued development of its pipeline of biologic therapeutics, several of which have entered clinical studies

Financing leaders: Future Industry Investment Fund, a private equity fund managed by SDIC Fund Management Corporation Limited, a subsidiary of State Development & Investment Corporation; Other “blue chip” investors including China Life Private Equity Limited, Milestone, Ping An, and Taikang Insurance Group.

Additional financial partners: Existing investors Legend Capital, Temasek, and Hillhouse Capital

#1. Moderna Therapeutics

Amount: $474 million

Type: Equity financing

Date announced: September 7

Purpose: Continued growth of its clinical pipeline and accelerated advancement of development candidates into clinical studies; construction of a new Good Manufacturing Practice (GMP) manufacturing facility in anticipation of increasing clinical activities across therapeutic areas; sustained investment in its mRNA technology platform at the pace of $100 million per year; continued expansion into new therapeutic areas and modalities

Financing leader: None denoted

Financial partners: Existing institutional investors and “world-class” strategic pharmaceutical partners, all undisclosed; as well as new institutional investors from the U.S., Europe, and Asia, also undisclosed
1 Company announced it raised $100 million on April 19, then submitted a Form D filing to the U.S. Securities and Exchange Commission on May 13 disclosing that its total offering amount was $110 million.
2 Company also disclosed that it had raised $50 million in Series A financing “late in 2015.” That financing was not announced at the time.
3 In announcing the $215 million equity financing, Intarcia said it “expects a larger second close with additional top-tier investors in 4Q.” No addition announcements had been made as of December 2. The company’s Form D, submitted September 15, discloses a total offering amount of $600 million.

Previous articlePerturb-Seq Combines CRISPR and Single-Cell RNA-Seq
Next articleSanger Spins Out Microbiotica to Develop Bacteriotherapies